drugset / Trial / NCT07402876
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
RandomizedParallel-groupTriple-blindTreatment
Summary
A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma
Timeline
- Start
- 2026-02
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | — | Other |